BME:GRFBiotechs
Assessing Grifols (BME:GRF) Valuation As Canada Tightens Rules And Debt Refinancing Advances
Grifols (BME:GRF) has been in focus after Health Canada imposed new regulatory conditions on its paid plasma collection centers, and the company moved to refinance and repurchase parts of its debt stack.
See our latest analysis for Grifols.
Those refinancing steps and the Health Canada conditions arrive after a mixed run for investors, with the latest €9.646 share price sitting alongside a 30 day share price return of 10.14%, a year to date share price return of 13.84%, and a 1 year total...